Wells Fargo analyst David Maris noted that the revised 2016-2019 outlook issued by Teva (TEVA) this morning, which now includes the Allergan (AGN) Generics deal that should be cleared soon by the FTC, exceeded expectations, but could still be conservative as strength in Teva's underlying franchises continues and the deal synergies start flowing through. Maris, who added that the tone of the company's guidance call was "generally positive" despite the company's view for erosion in the Copaxone franchise of $200M-$300M per year, has an Outperform rating and $68-$71 price target range on Teva shares.